Analyst Edward Nash of Canaccord Genuity maintained a Buy rating on Inventiva, retaining the price target of $20.00.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Edward Nash has given his Buy rating due to a combination of factors surrounding Inventiva’s promising developments and strategic positioning. The company’s pan-PPAR agonist, lanifibranor, is currently in Phase III development with the NATiV3 clinical trial, targeting patients with F2/F3 MASH. The anticipated top-line data from this trial, expected in the second half of 2026, is a significant catalyst, as the trial aims to meet dual primary endpoints of fibrosis improvement and MASH resolution, which are critical for regulatory approval.
Moreover, the mechanism of action of lanifibranor positions it well to address multiple aspects of the disease, particularly in patients with both MASH and Type 2 Diabetes (T2D). This patient group is considered a strategic target due to the lack of other investigational agents specifically designed for them and their higher cardiovascular risk profile. These factors, combined with the company’s confidence in meeting trial endpoints, underpin Nash’s optimistic outlook and Buy rating for Inventiva.
According to TipRanks, Nash is a 5-star analyst with an average return of 14.9% and a 45.35% success rate. Nash covers the Healthcare sector, focusing on stocks such as Corcept Therapeutics, Cardiol Therapeutics, and Madrigal Pharmaceuticals.